Unlike conventional Alzheimer’s drugs that largely manage memory loss and behavioural symptoms, donanemab targets amyloid-beta plaques ‘ abnormal protein deposits linked to the disease.
News
Alzheimer’s Lormalzi therapy offers hope; doctors for early diagnosis, close monitoring
May 17, 2026Unlike conventional Alzheimer’s drugs that largely manage memory loss and behavioural symptoms, donanemab targets amyloid-beta plaques ‘ abnormal protein deposits linked to the disease.